These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 1982761)

  • 41. Assessment of a relative therapeutic index between inhaled formoterol and salbuterol in asthma patients.
    Rosenborg J; Larsson P; Rott Z; Böcskei C; Poczi M; Juhász G
    Eur J Clin Pharmacol; 2002 Jul; 58(4):S61-7. PubMed ID: 12214580
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Salbutamol and high-intensity treadmill running in nonasthmatic highly conditioned athletes.
    Heir T; Stemshaug H
    Scand J Med Sci Sports; 1995 Aug; 5(4):231-6. PubMed ID: 7552768
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Bronchodilator subsensitivity to salbutamol after twice daily salmeterol in asthmatic patients.
    Grove A; Lipworth BJ
    Lancet; 1995 Jul; 346(8969):201-6. PubMed ID: 7616798
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Tolerance to bronchodilation during treatment with long-acting beta-agonists, a randomised controlled trial.
    Haney S; Hancox RJ
    Respir Res; 2005 Sep; 6(1):107. PubMed ID: 16168062
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The effect of adding ipratropium bromide to salbutamol in the treatment of acute asthma: a pooled analysis of three trials.
    Lanes SF; Garrett JE; Wentworth CE; Fitzgerald JM; Karpel JP
    Chest; 1998 Aug; 114(2):365-72. PubMed ID: 9726716
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Safety and tolerability of high-dose formoterol (Aerolizer) and salbutamol (pMDI) in patients with mild/moderate, persistent asthma.
    Kruse M; Rosenkranz B; Dobson C; Ayre G; Horowitz A
    Pulm Pharmacol Ther; 2005; 18(3):229-34. PubMed ID: 15707858
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Characteristics of reversible and nonreversible COPD and asthma and COPD overlap syndrome patients: an analysis of salbutamol Easyhaler data.
    Müller V; Gálffy G; Orosz M; Kováts Z; Odler B; Selroos O; Tamási L
    Int J Chron Obstruct Pulmon Dis; 2016; 11():93-101. PubMed ID: 26834466
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The pulmonary and extra-pulmonary effects of high-dose formoterol in COPD: a comparison with salbutamol.
    Goldkorn A; Diotto P; Burgess C; Weatherall M; Holt S; Beasley R; Siebers R
    Respirology; 2004 Mar; 9(1):102-8. PubMed ID: 14982610
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Intravenous treatment with rimiterol and salbutamol in asthma.
    Marlin GE; Turner P
    Br Med J; 1975 Jun; 2(5973):715-9. PubMed ID: 1139193
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Broxaterol: pharmacological profile of a unique structural feature.
    Della Bella D
    Respiration; 1989; 55 Suppl 2():10-4. PubMed ID: 2572035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Dose-effect relationship of the beta-agonists fenoterol and salbutamol in patients with asthma.
    Newhouse MT; Dolovich MB; Kazim F
    Chest; 1994 Jun; 105(6):1738-42. PubMed ID: 8205869
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Comparison of the effects of salmeterol and formoterol on airway tone and responsiveness over 24 hours in bronchial asthma.
    Rabe KF; Jörres R; Nowak D; Behr N; Magnussen H
    Am Rev Respir Dis; 1993 Jun; 147(6 Pt 1):1436-41. PubMed ID: 8503554
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A methacholine challenge dose-response study for development of a pharmacodynamic bioequivalence methodology for albuterol metered- dose inhalers.
    Creticos PS; Adams WP; Petty BG; Lewis LD; Singh GJ; Khattignavong AP; Molzon JA; Martinez MN; Lietman PS; Williams RL
    J Allergy Clin Immunol; 2002 Nov; 110(5):713-20. PubMed ID: 12417879
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dose equivalence and bronchoprotective effects of salmeterol and salbutamol in asthma.
    Higham MA; Sharara AM; Wilson P; Jenkins RJ; Glendenning GA; Ind PW
    Thorax; 1997 Nov; 52(11):975-80. PubMed ID: 9487346
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Broxaterol: therapeutic trials and safety profile.
    Ziment I
    Respiration; 1989; 55 Suppl 2():28-40. PubMed ID: 2572038
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Bronchodilator and bronchoprotective effects of salmeterol in young patients with asthma.
    Simons FE; Soni NR; Watson WT; Becker AB
    J Allergy Clin Immunol; 1992 Nov; 90(5):840-6. PubMed ID: 1358932
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Bronchodilator activity of a new inhaled beta 2-adrenoceptor agonist, tulobuterol and its protective effect in exercise-induced asthma.
    Patel KR
    Br J Clin Pharmacol; 1986 Feb; 21(2):234-7. PubMed ID: 3513811
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Metered dose inhaler salbutamol treatment of asthma in the ED: comparison of two doses with plasma levels.
    Rodrigo G; Rodrigo C
    Am J Emerg Med; 1996 Mar; 14(2):144-50. PubMed ID: 8924135
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Inhaled corticosteroids do not prevent the development of tolerance to the bronchoprotective effect of salmeterol.
    Kalra S; Swystun VA; Bhagat R; Cockcroft DW
    Chest; 1996 Apr; 109(4):953-6. PubMed ID: 8635376
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Protective action of broxaterol in bronchial spasm induced by ultrasonic mist].
    Aversa C; Scorrano F; Scoditti S; Pancosta G; Stomeo S
    Arch Monaldi Mal Torace; 1988; 43(3):243-8. PubMed ID: 2908378
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.